TipRanks on MSN
Kelun-Biotech’s ADC-PD-1 combo wins breakthrough therapy status in first-line lung cancer
An announcement from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( ($HK:6990) ) is now available. Sichuan Kelun-Biotech announced ...
NEW YORK, Dec. 1, 2025 /PRNewswire/ -- OncoPrecision Corporation ("OncoPrecision"), a translational therapeutics company developing novel antibody-based cancer therapies informed by large-scale ...
TipRanks on MSN
Kelun-Biotech wins NMPA IND nod for ITGB6-targeted ADC SKB105 and advances oncology collaboration with Crescent
The latest update is out from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( ($HK:6990) ). Sichuan Kelun-Biotech has received ...
DUBLIN--(BUSINESS WIRE)--The "Spotlight on Antibody-Drug Conjugates" report has been added to ResearchAndMarkets.com's offering. The first antibody-drug conjugate (ADC), Mylotarg, reached the market ...
TAMPA, Fla. and LONDON, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads today ...
The lively antibody-drug conjugate (ADC) space chalked another collaboration as Taipei, Taiwan-based Foreseen Biotechnology Co. Ltd. scored a global licensing agreement worth as much as $1.03 billion ...
Renesas Electronics Corporation, a premier supplier of advanced semiconductor solutions, today announced the industry’s highest-performance single-chip 14-bit, 1-MSPS successive-approximation-register ...
Norwood, Mass.—Analog Devices says its AD9254 14-bit, 150-MSPS analog-to-digital converter, with the best dynamic range of any competing ADC, consumes only 430 mW—a 50 percent reduction in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback